Results 201 to 210 of about 83,454 (234)

Antisense Oligonucleotide Delivery with Polyhexylcyanoacrylate Nanoparticles as Carriers

Methods, 1999
Polyalkylcyanoacrylate nanoparticles are effective colloidal drug carriers and were prepared by an emulsion polymerization process. Antisense oligonucleotides were loaded on the particles by adsorption. A cationic polymer, DEAE-dextran, was incorporated into the particle matrix or a cationic hydrophobic detergent (CTAB) was used to form a lipophilic ...
openaire   +2 more sources

In vitro transport and delivery of antisense oligonucleotides

2000
A variety of techniques are currently available to enhance the cellular uptake and pharmacological effectiveness of antisense oligonucleotides in the in vitro setting. The choice of technique will depend on the context of investigation, the likelihood of cytotoxity due to the delivery agents, and the ease and convenience of the approach.
J, Hughes, A, Astriab, H, Yoo, S, Alahari, E, Liang, D, Sergueev, B R, Shaw, R L, Juliano   +7 more
openaire   +2 more sources

Antisense drug delivery through the blood-brain barrier

Advanced Drug Delivery Reviews, 1995
The blood-brain barrier evolved to protect the brain against peripheral neurotransmitters, cytotoxins and microorganisms. This barrier prevents the delivery to brain of antisense oligomers and other potential therapeutics for the treatment of viral infections, tumors, and other brain disorders.
openaire   +2 more sources

Delivery Strategies for Antisense Oligonucleotide Therapeutics

2017
PrefaceOverview of Antisense Oligonucleotide Therapeutics and DeliveryDisrupting the Flow of Genetic Information with Antisense Oligodeoxynucleotides: Research and Therapeutic Applications, D. Kregenow, M.Z. Ratajczak, and A. GewirtzCellular Delivery of Ribozymes, D.A. Elkins and J.J.
openaire   +1 more source

Intrabody tissue-specific delivery of antisense conjugates in animals: Ligand-linker-antisense oligomer conjugates

2000
Publisher Summary The selective inhibition of gene expression through specific oligonucleotide binding to key mRNA target sequences is the goal of antisense strategies. However, from the beginning, antisense strategies have faced several obstacles, such as in vivo stability of the oligonucleotide, cellular uptake, efficiency of hybridization of the ...
R J, Duff, S F, Deamond, C, Roby, Y, Zhou, P O, Ts'o   +4 more
openaire   +2 more sources

Advances in antisense efficacy and delivery

Trends in Biotechnology, 1995
S, Agrawal, S, Akhtar
openaire   +2 more sources

Lipoprotein-mediated delivery of antisense oligonucleotides

Journal of Controlled Release, 1992
DE SMIDT P C, LE DOAN T, DE FALCO S, VAN BERKEL T J C   +3 more
openaire   +2 more sources

Antisense oligonucleotide therapeutics: drug delivery and targeting

Advanced Drug Delivery Reviews, 1996
Abstract Oligonucleotide(ON)-based therapy, although in an early stage of development, promises to provide new and highly specific tools for the treatment of human diseases such as virus-associated illnesses and cancers. Like gene therapy, ON therapy is a rapidly growing field with great therapeutic potential. However, the two types of therapy differ
openaire   +1 more source

Development of Delivery Systems for Antisense Oligonucleotides

1996
In order to construct the strategy for in vivo antisense oligonucleotide delivery systems, pharmacokinetic properties of a model antisense oligonucleotide, c-myc antisense 20-mer, were studied at organ level using organ perfusion experiments. In the liver, approximately 30–40% of injected oligonucleotides were extracted by the organ during single ...
Yoshinobu Takakura, Ram I. Mahato, Takehiko Nomura, Kenzo Sawai, Mitsunobu Yoshida, Taro Kanamaru, Mitsuru Hashida   +6 more
openaire   +1 more source

Planning for post‐pandemic cancer care delivery: Recovery or opportunity for redesign?

Ca-A Cancer Journal for Clinicians, 2021
Pelin Cinar, Daniela A Bota, Kathryn A Gold   +2 more
exaly